Eastern asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma

The largest burden of hepatocellular carcinoma (HCC) lies in Asia, secondary to hepatitis B virus (HBV) infection. Improved survival with sorafenib has fostered new research but many challenges remain in designing clinical trials. The disease, its management, and populations affected by it are heter...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeo, Winnie, Chen, Pei-Jer, Furuse, Junji, Han, Kwang-Hyub, Hsu, Chiun, Lim, Ho-Yeong, Moon, Hanlim, Qin, Shukui, Yeoh, Ee-Min, Ye, Sheng-Long
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2989333/
https://www.ncbi.nlm.nih.gov/pubmed/21062497
http://dx.doi.org/10.1186/1471-2407-10-620

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2989333/
https://www.ncbi.nlm.nih.gov/pubmed/21062497
http://dx.doi.org/10.1186/1471-2407-10-620

Ejemplares similares